Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotron Ltd
Retained Earnings
Biotron Ltd
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Retained Earnings
-AU$59.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Retained Earnings
-$905.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
|
CSL Ltd
ASX:CSL
|
Retained Earnings
$18.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Retained Earnings
-AU$58m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Retained Earnings
-AU$52.1m
|
CAGR 3-Years
44%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Retained Earnings
-AU$222.4m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-19%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Retained Earnings?
Retained Earnings
-59.3m
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Retained Earnings amounts to -59.3m AUD.
What is Biotron Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-5%
Over the last year, the Retained Earnings growth was -3%. The average annual Retained Earnings growth rates for Biotron Ltd have been -5% over the past three years , -4% over the past five years , and -5% over the past ten years .
